HIGHLIGHTS
- who: Madis Parksepp and collaborators from the Institute of Clinical Medicine, University of Tartu, Tartu, Estonia have published the article: A Marked Low-Grade Inflammation and a Significant Deterioration in Metabolic Status in First-Episode Schizophrenia: A Five-Year Follow-Up Study, in the Journal: Metabolites 2022, 983 of /2022/
- what: The aim of this study was to evaluate how schizophrenia spectrum disorders and applied long-term (5.1 years) antipsychotic (AP) treatment affect the serum level of acylcarnitines (ACs) cytokines and metabolic biomarkers and to characterize the dynamics of inflammatory and metabolic changes in . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.